Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
•Immune-induced vaccination has been suggested as a key global strategy for SARS-CoV-2.•Previous-natural infection subjects presented higher value of antibodies after 12 days.•Antibodies levels did not differ between males and females.•Antibodies levels were lower in subjects older than 60 years aft...
Saved in:
Published in | Clinica chimica acta Vol. 519; pp. 60 - 63 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.08.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 0009-8981 1873-3492 1873-3492 |
DOI | 10.1016/j.cca.2021.04.006 |
Cover
Abstract | •Immune-induced vaccination has been suggested as a key global strategy for SARS-CoV-2.•Previous-natural infection subjects presented higher value of antibodies after 12 days.•Antibodies levels did not differ between males and females.•Antibodies levels were lower in subjects older than 60 years after 12 days, not at 28 days.
Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed.
163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively.
Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28.
Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant. |
---|---|
AbstractList | Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed.
163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively.
Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28.
Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant. •Immune-induced vaccination has been suggested as a key global strategy for SARS-CoV-2.•Previous-natural infection subjects presented higher value of antibodies after 12 days.•Antibodies levels did not differ between males and females.•Antibodies levels were lower in subjects older than 60 years after 12 days, not at 28 days. Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed. 163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively. Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28. Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant. Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed.BACKGROUNDVaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed.163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively.METHODS163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively.Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28.RESULTSSignificant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28.Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant.CONCLUSIONSOur study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant. |
Author | Cosma, Chiara Cianci, Vito Barbaro, Francesco Dall'Olmo, Luigi Basso, Daniela Padoan, Andrea Plebani, Mario Cattelan, Annamaria Rocca, Foscarina della |
Author_xml | – sequence: 1 givenname: Andrea orcidid: 0000-0003-1284-7885 surname: Padoan fullname: Padoan, Andrea organization: Department of Medicine-DIMED, University of Padova, Italy – sequence: 2 givenname: Luigi surname: Dall'Olmo fullname: Dall'Olmo, Luigi organization: Department of Surgical Oncological and Gastroenterological Sciences – DISCOG, University of Padova, Italy – sequence: 3 givenname: Foscarina della surname: Rocca fullname: Rocca, Foscarina della organization: Emergency Department, Padua University Hospital, Padua, Italy – sequence: 4 givenname: Francesco surname: Barbaro fullname: Barbaro, Francesco organization: Infective and Tropical Disease Unit, Padua University Hospital, Padua, Italy – sequence: 5 givenname: Chiara surname: Cosma fullname: Cosma, Chiara organization: Department of Laboratory Medicine, University-Hospital of Padova, Italy – sequence: 6 givenname: Daniela orcidid: 0000-0001-8745-6171 surname: Basso fullname: Basso, Daniela organization: Department of Medicine-DIMED, University of Padova, Italy – sequence: 7 givenname: Annamaria surname: Cattelan fullname: Cattelan, Annamaria organization: Infective and Tropical Disease Unit, Padua University Hospital, Padua, Italy – sequence: 8 givenname: Vito surname: Cianci fullname: Cianci, Vito organization: Emergency Department, Padua University Hospital, Padua, Italy – sequence: 9 givenname: Mario orcidid: 0000-0002-0270-1711 surname: Plebani fullname: Plebani, Mario email: mario.plebani@unipd.it organization: Department of Medicine-DIMED, University of Padova, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33857476$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kctuFDEQRS0URCaBD2CDvGTTjd3uhy0kpBCFhxSRTbK23OVq2kOPPdieoOTr8WhCBCyysEp2nXvLqntCjnzwSMhrzmrOeP9uXQOYumENr1lbM9Y_IysuB1GJVjVHZMUYU5VUkh-Tk5TW5dqynr8gx0LIbmiHfkWmM5_dGOwdjZi2wSekOdDJxZSp8ZYmhFCKDaURJvrx2zXvm7GhzlNDIcwh5v07zCYayBjdPVo6o1nyDCYi_RXiD4zpJXk-mSXhq4d6Sm4-XVyff6kurz5_PT-7rKDjQ64En7iVyliOjWKjaadhlKNABWyyvZCDsYBGCQ7IjGyUaKwUYIRqOyhnEKfkw8F3uxs3WGCfo1n0NrqNiXc6GKf_7Xg36-_hVkvW9arlxeDtg0EMP3eYst64BLgsxmPYJd10vO2UZD0r6Ju_Zz0O-bPcAvADADGkFHF6RDjT-wD1WpcA9T5AzVpdAiya4T8NuGyyC_vvuuVJ5fuDEst-bx1GncChB7QuImRtg3tC_Rsq5LX7 |
CitedBy_id | crossref_primary_10_3390_vaccines9060652 crossref_primary_10_1515_cclm_2022_0418 crossref_primary_10_3390_vaccines10060909 crossref_primary_10_1016_j_clinbiochem_2023_03_003 crossref_primary_10_3390_vaccines10122125 crossref_primary_10_3390_diseases13030078 crossref_primary_10_3389_fimmu_2023_1136308 crossref_primary_10_3390_vaccines9121377 crossref_primary_10_1515_cclm_2021_0687 crossref_primary_10_1002_jmv_27096 crossref_primary_10_3390_diagnostics11060941 crossref_primary_10_3389_fimmu_2021_779212 crossref_primary_10_3390_biomedicines11102661 crossref_primary_10_1186_s13027_021_00375_2 crossref_primary_10_3390_jcm12093172 crossref_primary_10_1080_22221751_2021_1953403 crossref_primary_10_3389_fimmu_2021_752233 crossref_primary_10_3390_vaccines11010051 crossref_primary_10_3390_vaccines10050734 crossref_primary_10_3390_microorganisms10091812 crossref_primary_10_3390_vaccines10010064 crossref_primary_10_1515_cclm_2022_0322 crossref_primary_10_3390_vaccines10091443 crossref_primary_10_1016_j_cca_2021_10_035 crossref_primary_10_3390_tropicalmed9030061 crossref_primary_10_3390_vaccines9111322 crossref_primary_10_1002_jmv_27420 crossref_primary_10_1016_j_vaccine_2021_11_081 crossref_primary_10_1515_cclm_2022_0170 crossref_primary_10_3390_diagnostics11091709 crossref_primary_10_1016_j_cca_2021_10_028 crossref_primary_10_1016_j_heliyon_2022_e09438 crossref_primary_10_3390_vaccines9101092 crossref_primary_10_1136_jclinpath_2021_207572 crossref_primary_10_1016_j_mayocp_2021_08_013 crossref_primary_10_1016_j_jiph_2023_06_014 crossref_primary_10_1016_j_celrep_2022_110336 crossref_primary_10_1016_j_heliyon_2023_e16547 crossref_primary_10_3390_vaccines10040531 crossref_primary_10_3390_vaccines10081169 crossref_primary_10_1515_cclm_2021_1247 crossref_primary_10_1186_s12879_024_09338_5 crossref_primary_10_3390_vaccines9060672 crossref_primary_10_1016_j_jcv_2021_105057 crossref_primary_10_1186_s12916_022_02297_1 crossref_primary_10_1515_labmed_2021_0156 crossref_primary_10_1016_j_jcvp_2022_100094 crossref_primary_10_1128_spectrum_01181_21 crossref_primary_10_1515_cclm_2023_0129 crossref_primary_10_3390_vaccines9111357 crossref_primary_10_1016_j_eclinm_2021_101253 crossref_primary_10_1186_s13027_022_00451_1 crossref_primary_10_1038_s41392_022_01007_w crossref_primary_10_1515_cclm_2021_0703 crossref_primary_10_1016_j_cca_2022_02_014 crossref_primary_10_7759_cureus_45143 crossref_primary_10_1080_10408363_2022_2038539 crossref_primary_10_1080_23744235_2021_1974540 crossref_primary_10_1111_all_15007 crossref_primary_10_3390_vaccines11071183 crossref_primary_10_3390_vaccines9111223 crossref_primary_10_1016_j_molimm_2023_09_001 crossref_primary_10_3390_vaccines10030474 crossref_primary_10_1002_jmv_27688 crossref_primary_10_3390_jpm12060994 crossref_primary_10_2139_ssrn_4016384 |
Cites_doi | 10.1016/j.cca.2020.05.050 10.1101/2021.02.23.21249481 10.1126/science.abb3221 10.1038/s41591-020-0913-5 10.1056/NEJMc2101667 10.1056/NEJMoa2035389 10.1515/cclm-2021-0023 10.1001/jama.2021.4388 10.3390/jcm9123989 10.1016/S0140-6736(21)00501-8 10.1056/NEJMoa2034577 10.1101/2021.03.10.21253260 10.1038/s41591-020-01179-4 10.1056/NEJMoa2028436 10.1056/NEJMoa2027906 10.1016/j.jcv.2021.104784 10.1016/j.ebiom.2020.103087 |
ContentType | Journal Article |
Copyright | 2021 Elsevier B.V. Copyright © 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V. |
Copyright_xml | – notice: 2021 Elsevier B.V. – notice: Copyright © 2021 Elsevier B.V. All rights reserved. – notice: 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V. |
DBID | AAYXX CITATION NPM 7X8 5PM |
DOI | 10.1016/j.cca.2021.04.006 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry |
EISSN | 1873-3492 |
EndPage | 63 |
ExternalDocumentID | PMC8056941 33857476 10_1016_j_cca_2021_04_006 S0009898121001297 |
Genre | Journal Article |
GroupedDBID | --- --K --M .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29B 4.4 457 4G. 53G 5GY 5VS 6J9 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFNM ABFRF ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q G8K GBLVA HLW HVGLF HZ~ IHE J1W J5H K-O KOM L7B LCYCR LX3 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG RNS ROL RPZ SBG SDF SDG SDP SES SEW SPCBC SSH SSU SSZ T5K WH7 WUQ X7M XPP ZA5 ZGI ~02 ~G- AATTM AAXKI AAYWO AAYXX ABDPE ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD AGRNS NPM 7X8 ACLOT 5PM |
ID | FETCH-LOGICAL-c517t-31f1d89ad1e290ba4f7b8b3e9c0fd6387adcea931ce0a82932d83ca3945c94573 |
IEDL.DBID | AIKHN |
ISSN | 0009-8981 1873-3492 |
IngestDate | Thu Aug 21 14:34:52 EDT 2025 Sun Sep 28 15:58:25 EDT 2025 Mon Jul 21 05:33:50 EDT 2025 Thu Sep 18 00:15:20 EDT 2025 Thu Apr 24 23:09:33 EDT 2025 Fri Feb 23 02:45:17 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 BNT162b2 Immunological response Antibody SARS-CoV-2 vaccine Serology Immunoassays |
Language | English |
License | Copyright © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c517t-31f1d89ad1e290ba4f7b8b3e9c0fd6387adcea931ce0a82932d83ca3945c94573 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-8745-6171 0000-0002-0270-1711 0000-0003-1284-7885 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8056941 |
PMID | 33857476 |
PQID | 2514598060 |
PQPubID | 23479 |
PageCount | 4 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8056941 proquest_miscellaneous_2514598060 pubmed_primary_33857476 crossref_primary_10_1016_j_cca_2021_04_006 crossref_citationtrail_10_1016_j_cca_2021_04_006 elsevier_sciencedirect_doi_10_1016_j_cca_2021_04_006 |
PublicationCentury | 2000 |
PublicationDate | 2021-08-01 |
PublicationDateYYYYMMDD | 2021-08-01 |
PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Clinica chimica acta |
PublicationTitleAlternate | Clin Chim Acta |
PublicationYear | 2021 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Prendecki, Clarke, Brown, Cox, Gleeson, Guckian, Randell, Pria, Lightstone, Xu, Barclay, McAdoo, Kelleher, Willicombe (b0080) 2021; 6736 Plebani (b0060) 2020; 61 F. Krammer, K. Srivastava, H. Alshammary, A.A. Amoako, M.H. Awawda, K.F. Beach, M.C. Bermúdez-González, D.A. Bielak, J.M. Carreño, R.L. Chernet, L.Q. Eaker, E.D. Ferreri, D.L. Floda, C.R. Gleason, J.Z. Hamburger, K. Jiang, G. Kleiner, D. Jurczyszak, J.C. Matthews, W.A. Mendez, I. Nabeel, L.C.F. Mulder, A.J. Raskin, K.T. Russo, A.-B.T. Salimbangon, M. Saksena, A.S. Shin, G. Singh, L.A. Sominsky, D. Stadlbauer, A. Wajnberg, V. Simon, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine, N. Engl. J. Med. (2021) NEJMc2101667. Walsh, Frenck, Falsey, Kitchin, Absalon, Gurtman, Lockhart, Neuzil, Mulligan, Bailey, Swanson, Li, Koury, Kalina, Cooper, Fontes-Garfias, Shi, Türeci, Tompkins, Lyke, Raabe, Dormitzer, Jansen, Şahin, Gruber (b0025) 2020; 383 Edara, Hudson, Xie, Ahmed, Suthar (b0090) 2021 Baden, El Sahly, Essink, Kotloff, Frey, Novak, Diemert, Spector, Rouphael, Creech, McGettigan, Khetan, Segall, Solis, Brosz, Fierro, Schwartz, Neuzil, Corey, Gilbert, Janes, Follmann, Marovich, Mascola, Polakowski, Ledgerwood, Graham, Bennett, Pajon, Knightly, Leav, Deng, Zhou, Han, Ivarsson, Miller, Zaks (b0070) 2021; 384 F. Barbaro, F. Della Rocca, A. Padoan, A. Aita, V. Cianci, D. Basso, A. Cattelan, D. Donato, M. Plebani, L. Dall’Olmo, A longitudinal study of healthcare workers’ surveillance during the ongoing COVID-19 Epidemics in Italy: is SARS-CoV-2 still a threat for the Health-care System? MedRxiv (2021) 2021.02.23.21249481, doi: 10.1101/2021.02.23.21249481. Poljak, Oštrbenk Valenčak, Štamol, Seme (b0050) 2021; 137 Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart, Perez, Pérez Marc, Moreira, Zerbini, Bailey, Swanson, Roychoudhury, Koury, Li, Kalina, Cooper, Frenck, Hammitt, Türeci, Nell, Schaefer, Ünal, Tresnan, Mather, Dormitzer, Şahin, Jansen, Gruber (b0005) 2020; 383 Plebani, Padoan, Negrini, Carpinteri, Sciacovelli (b0030) 2020; 509 Amanat, Stadlbauer, Strohmeier, Nguyen, Chromikova, McMahon, Jiang, Arunkumar, Jurczyszak, Polanco, Bermudez-Gonzalez, Kleiner, Aydillo, Miorin, Fierer, Lugo, Kojic, Stoever, Liu, Cunningham-Rundles, Felgner, Moran, García-Sastre, Caplivski, Cheng, Kedzierska, Vapalahti, Hepojoki, Simon, Krammer (b0035) 2020; 26 Schaffner, Risch, Aeschbacher, Risch, Weber, Thiel, Jüngert, Pichler, Grossmann, Wohlwend, Lung, Hillmann, Bigler, Bodmer, Imperiali, Renz, Kohler, Vernazza, Kahlert, Twerenbold, Paprotny, Conen, Risch (b0055) 2020; 9 C. Manisty, A.D. Otter, T.A. Treibel, ine McKnight, D.M. Altmann, T. Brooks, M. Noursadeghi, R.J. Boyton, A. Semper, J.C. Moon, Correspondence antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals, Lancet 6736 (2021) 2–3. European center for disease prevention and control (ECDC), Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU / EEA and the UK Key findings, (2020) 1–22. Anderson, Rouphael, Widge, Jackson, Roberts, Makhene, Chappell, Denison, Stevens, Pruijssers, McDermott, Flach, Lin, Doria-Rose, O’Dell, Schmidt, Corbett, Swanson, Padilla, Neuzil, Bennett, Leav, Makowski, Albert, Cross, Edara, Floyd, Suthar, Martinez, Baric, Buchanan, Luke, Phadke, Rostad, Ledgerwood, Graham, Beigel (b0015) 2020; 383 Li, Pei, Chen, Song, Zhang, Yang, Shaman (b0065) 2020; 368 F. Bonelli, F.A. Blocki, T. Bunnell, E. Chu, O.A. De La, D.G. Grenache, G. Marzucchi, E. Montomoli, L. Okoye, L. Pallavicini, V.A. Streva, A. Torelli, A. Wagner, D. Zanin, C. Zierold, J.J. Wassenberg, Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021 [ahead of print], doi: 10.1515/cclm-2021-0023. Barrett, Belij-Rammerstorfer, Dold, Ewer, Folegatti, Gilbride, Halkerston, Hill, Jenkin, Stockdale, Verheul, Aley, Angus, Bellamy, Berrie, Bibi, Bittaye, Carroll, Cavell, Clutterbuck, Edwards, Flaxman, Fuskova, Gorringe, Hallis, Kerridge, Lawrie, Linder, Liu, Madhavan, Makinson, Mellors, Minassian, Moore, Mujadidi, Plested, Poulton, Ramasamy, Robinson, Rollier, Song, Snape, Tarrant, Taylor, Thomas, Voysey, Watson, Wright, Douglas, Green, Hill, Lambe, Gilbert, Pollard (b0010) 2021; 27 A. Padoan, F. Bonfante, C. Cosma, C. Di Chiara, L. Sciacovelli, M. Pagliari, A. Bortolami, P. Costenaro, G. Musso, D. Basso, C. Giaquinto, M. Plebani, Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers, Clin. Chem. Lab. Med. (2021) (accepted for pubblication on April 1st, 2021). 10.1016/j.cca.2021.04.006_b0085 10.1016/j.cca.2021.04.006_b0020 10.1016/j.cca.2021.04.006_b0075 10.1016/j.cca.2021.04.006_b0045 Schaffner (10.1016/j.cca.2021.04.006_b0055) 2020; 9 Polack (10.1016/j.cca.2021.04.006_b0005) 2020; 383 Baden (10.1016/j.cca.2021.04.006_b0070) 2021; 384 Plebani (10.1016/j.cca.2021.04.006_b0060) 2020; 61 Edara (10.1016/j.cca.2021.04.006_b0090) 2021 Poljak (10.1016/j.cca.2021.04.006_b0050) 2021; 137 Prendecki (10.1016/j.cca.2021.04.006_b0080) 2021; 6736 Plebani (10.1016/j.cca.2021.04.006_b0030) 2020; 509 Barrett (10.1016/j.cca.2021.04.006_b0010) 2021; 27 Amanat (10.1016/j.cca.2021.04.006_b0035) 2020; 26 Li (10.1016/j.cca.2021.04.006_b0065) 2020; 368 Anderson (10.1016/j.cca.2021.04.006_b0015) 2020; 383 Walsh (10.1016/j.cca.2021.04.006_b0025) 2020; 383 10.1016/j.cca.2021.04.006_b0040 10.1016/j.cca.2021.04.006_b0095 |
References_xml | – volume: 27 start-page: 279 year: 2021 end-page: 288 ident: b0010 article-title: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses publication-title: Nat. Med. – volume: 509 start-page: 1 year: 2020 end-page: 7 ident: b0030 article-title: Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? publication-title: Clin. Chim. Acta. – volume: 383 start-page: 2427 year: 2020 end-page: 2438 ident: b0015 article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults publication-title: N. Engl. J. Med. – reference: European center for disease prevention and control (ECDC), Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU / EEA and the UK Key findings, (2020) 1–22. – volume: 6736 start-page: 10 year: 2021 end-page: 12 ident: b0080 article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine publication-title: Lancet – volume: 137 year: 2021 ident: b0050 article-title: Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain publication-title: J. Clin. Virol. – reference: F. Bonelli, F.A. Blocki, T. Bunnell, E. Chu, O.A. De La, D.G. Grenache, G. Marzucchi, E. Montomoli, L. Okoye, L. Pallavicini, V.A. Streva, A. Torelli, A. Wagner, D. Zanin, C. Zierold, J.J. Wassenberg, Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021 [ahead of print], doi: 10.1515/cclm-2021-0023. – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: b0070 article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine publication-title: N. Engl. J. Med. – reference: F. Krammer, K. Srivastava, H. Alshammary, A.A. Amoako, M.H. Awawda, K.F. Beach, M.C. Bermúdez-González, D.A. Bielak, J.M. Carreño, R.L. Chernet, L.Q. Eaker, E.D. Ferreri, D.L. Floda, C.R. Gleason, J.Z. Hamburger, K. Jiang, G. Kleiner, D. Jurczyszak, J.C. Matthews, W.A. Mendez, I. Nabeel, L.C.F. Mulder, A.J. Raskin, K.T. Russo, A.-B.T. Salimbangon, M. Saksena, A.S. Shin, G. Singh, L.A. Sominsky, D. Stadlbauer, A. Wajnberg, V. Simon, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine, N. Engl. J. Med. (2021) NEJMc2101667. – volume: 26 start-page: 1033 year: 2020 end-page: 1036 ident: b0035 article-title: A serological assay to detect SARS-CoV-2 seroconversion in humans publication-title: Nat. Med. – year: 2021 ident: b0090 article-title: Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination publication-title: JAMA – reference: C. Manisty, A.D. Otter, T.A. Treibel, ine McKnight, D.M. Altmann, T. Brooks, M. Noursadeghi, R.J. Boyton, A. Semper, J.C. Moon, Correspondence antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals, Lancet 6736 (2021) 2–3. – volume: 368 start-page: 489 year: 2020 end-page: 493 ident: b0065 article-title: Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) publication-title: Science (80) – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: b0005 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. – reference: F. Barbaro, F. Della Rocca, A. Padoan, A. Aita, V. Cianci, D. Basso, A. Cattelan, D. Donato, M. Plebani, L. Dall’Olmo, A longitudinal study of healthcare workers’ surveillance during the ongoing COVID-19 Epidemics in Italy: is SARS-CoV-2 still a threat for the Health-care System? MedRxiv (2021) 2021.02.23.21249481, doi: 10.1101/2021.02.23.21249481. – volume: 9 start-page: 3989 year: 2020 ident: b0055 article-title: Characterization of a Pan-immunoglobulin assay quantifying antibodies directed against the receptor binding domain of the SARS-CoV-2 S1-subunit of the spike protein: a population-based study publication-title: J. Clin. Med. – volume: 383 start-page: 2439 year: 2020 end-page: 2450 ident: b0025 article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates publication-title: N. Engl. J. Med. – reference: A. Padoan, F. Bonfante, C. Cosma, C. Di Chiara, L. Sciacovelli, M. Pagliari, A. Bortolami, P. Costenaro, G. Musso, D. Basso, C. Giaquinto, M. Plebani, Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers, Clin. Chem. Lab. Med. (2021) (accepted for pubblication on April 1st, 2021). – volume: 61 year: 2020 ident: b0060 article-title: SARS-CoV-2 antibody-based SURVEILLANCE: new light in the SHADOW publication-title: EBioMedicine. – volume: 509 start-page: 1 year: 2020 ident: 10.1016/j.cca.2021.04.006_b0030 article-title: Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? publication-title: Clin. Chim. Acta. doi: 10.1016/j.cca.2020.05.050 – ident: 10.1016/j.cca.2021.04.006_b0040 doi: 10.1101/2021.02.23.21249481 – volume: 368 start-page: 489 year: 2020 ident: 10.1016/j.cca.2021.04.006_b0065 article-title: Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) publication-title: Science (80) doi: 10.1126/science.abb3221 – volume: 26 start-page: 1033 year: 2020 ident: 10.1016/j.cca.2021.04.006_b0035 article-title: A serological assay to detect SARS-CoV-2 seroconversion in humans publication-title: Nat. Med. doi: 10.1038/s41591-020-0913-5 – ident: 10.1016/j.cca.2021.04.006_b0075 doi: 10.1056/NEJMc2101667 – volume: 384 start-page: 403 year: 2021 ident: 10.1016/j.cca.2021.04.006_b0070 article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2035389 – ident: 10.1016/j.cca.2021.04.006_b0095 doi: 10.1515/cclm-2021-0023 – year: 2021 ident: 10.1016/j.cca.2021.04.006_b0090 article-title: Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination publication-title: JAMA doi: 10.1001/jama.2021.4388 – volume: 9 start-page: 3989 year: 2020 ident: 10.1016/j.cca.2021.04.006_b0055 article-title: Characterization of a Pan-immunoglobulin assay quantifying antibodies directed against the receptor binding domain of the SARS-CoV-2 S1-subunit of the spike protein: a population-based study publication-title: J. Clin. Med. doi: 10.3390/jcm9123989 – ident: 10.1016/j.cca.2021.04.006_b0085 doi: 10.1016/S0140-6736(21)00501-8 – volume: 383 start-page: 2603 year: 2020 ident: 10.1016/j.cca.2021.04.006_b0005 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 – ident: 10.1016/j.cca.2021.04.006_b0020 – ident: 10.1016/j.cca.2021.04.006_b0045 doi: 10.1101/2021.03.10.21253260 – volume: 27 start-page: 279 year: 2021 ident: 10.1016/j.cca.2021.04.006_b0010 article-title: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses publication-title: Nat. Med. doi: 10.1038/s41591-020-01179-4 – volume: 383 start-page: 2427 year: 2020 ident: 10.1016/j.cca.2021.04.006_b0015 article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2028436 – volume: 383 start-page: 2439 year: 2020 ident: 10.1016/j.cca.2021.04.006_b0025 article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2027906 – volume: 137 year: 2021 ident: 10.1016/j.cca.2021.04.006_b0050 article-title: Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2021.104784 – volume: 6736 start-page: 10 year: 2021 ident: 10.1016/j.cca.2021.04.006_b0080 article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine publication-title: Lancet – volume: 61 year: 2020 ident: 10.1016/j.cca.2021.04.006_b0060 article-title: SARS-CoV-2 antibody-based SURVEILLANCE: new light in the SHADOW publication-title: EBioMedicine. doi: 10.1016/j.ebiom.2020.103087 |
SSID | ssj0004061 |
Score | 2.572793 |
Snippet | •Immune-induced vaccination has been suggested as a key global strategy for SARS-CoV-2.•Previous-natural infection subjects presented higher value of... Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of... |
SourceID | pubmedcentral proquest pubmed crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 60 |
SubjectTerms | Antibody BNT162b2 COVID-19 Immunoassays Immunological response SARS-CoV-2 vaccine Serology |
Title | Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers |
URI | https://dx.doi.org/10.1016/j.cca.2021.04.006 https://www.ncbi.nlm.nih.gov/pubmed/33857476 https://www.proquest.com/docview/2514598060 https://pubmed.ncbi.nlm.nih.gov/PMC8056941 |
Volume | 519 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61Wwm4ICiv5VEZiRNSqJ3YsX1cVlQLqHtqpd4sxw81CCXVNj3Agd_OePOABdQDhySKnZFsjz3zTTyeAXgTSyHyMvqM6lBm3DqWWSpjJrlHsFxwKUM6jXy6Llfn_NOFuNiD5XgWJrlVDrK_l-lbaT2UHA-jeXxV1-mML03JD1MErPQ3Re7DQY7aXs3gYPHx82r963gkLdmYUC0RjJubWzcv7AFaiTnbBjxNeY_-rZ7-hp9_elH-ppZOHsD9AU-SRd_kh7AXmkO4uxzTuB3CndNh9_wRxEXT1VXrv5FN7xkbSNeSWCMAJLbx5DoZx574FivaSN6vz1iZVzmpG2JJyqS76VK5m2I8fw-eXE4OZCT5eCGafAznJx_OlqtsyLOQOcFkh2I4Mq-09SzkmlaWR1mpqgja0ehxfUqLfbS6YC5QqxAf5F4VzhaaC4eXLJ7ArGmb8AwIAgquUwhAVHo8CFcFvDl8qDIIpsIc6Di8xg1ByFMujK9m9Db7YpAjJnHEUG6QI3N4O5Fc9RE4bvuYjzwzO9PIoIa4jez1yF-D7El7JrYJ7c21QfjHhVa0pHN42vN7agVa9wKtMaSWOzNh-iCF7t6taerLbQhvhbhTc_b8_5r7Au6lt94P8SXMus1NeIXYqKuOYP_dD3Y0rICfUEcNfQ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SDTS9lDZ9bZ8q9FQwkWzZso_bpWHTZPe0gdyErAdxKXbYOIfm12dm_Wi3LTn0YBv0AEkjzXxjzQPgU8jSNM6Ci3jhs0gaKyLDVYiUdAiWE6mUJ2_k5SpbnMtvF-nFHswHXxgyq-x5f8fTt9y6LznqV_PoqqrIx5dT8kOKgEV_U9QD2JeU1HoC-7OT08Xql3skz8SQUI06DJebWzMvnAFqibHYBjylvEf_Fk9_w88_rSh_E0vHT-BxjyfZrBvyU9jz9SEczIc0bofwcNnfnj-DMKvbqmzcT7bpLGM9axsWKgSAzNSOXZNy7JhrsKIJ7MtqLbK4jFlVM8Mok-6mpXI7xni-9Y5djgZkjGy8EE0-h_Pjr-v5IurzLEQ2FapFNhyEywvjhI8LXhoZVJmXiS8sDw7PpzI4R1MkwnpucsQHscsTa5JCphYflbyASd3U_hUwBBSyoBCAKPSkT23p8WXxk2c-FbmfAh-WV9s-CDnlwvihB2uz7xopookimkuNFJnC57HLVReB477GcqCZ3tlGGiXEfd0-DvTVSB66MzG1b26uNcI_mRY5z_gUXnb0HkeB2n2K2hj2Vjs7YWxAobt3a-rqchvCO0fcWUjx-v-G-wEOFuvlmT47WZ2-gUdU09kkvoVJu7nx7xAnteX7_hzcAae9D2M |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibody+response+to+first+and+second+dose+of+BNT162b2+in+a+cohort+of+characterized+healthcare+workers&rft.jtitle=Clinica+chimica+acta&rft.au=Padoan%2C+Andrea&rft.au=Dall%27Olmo%2C+Luigi&rft.au=Rocca%2C+Foscarina+della&rft.au=Barbaro%2C+Francesco&rft.date=2021-08-01&rft.pub=Elsevier+B.V&rft.issn=0009-8981&rft.eissn=1873-3492&rft.volume=519&rft.spage=60&rft.epage=63&rft_id=info:doi/10.1016%2Fj.cca.2021.04.006&rft_id=info%3Apmid%2F33857476&rft.externalDocID=PMC8056941 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-8981&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-8981&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-8981&client=summon |